1Semana
High R&D expenditure is not negative: it is positive for a research-based biotech company!
Perhaps disadvantageous for the balance sheet analyst, but essential for the company and reassuring for an investor with a professional biotech background 😃: The investment is working - in any case.
Perhaps disadvantageous for the balance sheet analyst, but essential for the company and reassuring for an investor with a professional biotech background 😃: The investment is working - in any case.
•
11
•
1Semana
@Gomerdoc it's more about the fact that they have risen so drastically and not that it's bad. Otherwise, of course, you're right
•
11
•